News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytonet LLC’s Liver Cell Therapy May Be Effective In Stabilizing Children With Severe Urea Cycle Disorders Awaiting Liver Transplant


7/28/2014 9:01:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO & RALEIGH-DURHAM, N.C.--(BUSINESS WIRE)--Cytonet announced today that new research on its investigational liver cell therapy (LCT) was presented on July 27, 2014 at the 2014 World Transplant Congress (WTC) in San Francisco. The presentation, titled “Clinical Outcome in Children with Urea Cycle Deficiencies after Liver Cell Therapy in Comparison to a Control Group,” demonstrates how investigational liver cell therapy may help temporarily stabilize pediatric patients with urea cycle disorders (UCD) as they await liver transplantation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES